Jump to content

Otsuka Pharmaceutical: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Tags: Mobile edit Mobile app edit Android app edit
Monkbot (talk | contribs)
Bots
3,695,952 edits
m Task 18 (cosmetic): eval 13 templates: del empty params (3×); hyphenate params (10×);
Line 59: Line 59:


==History==
==History==
OPC's parent company Otsuka Holdings Co. Ltd. joined the [[Tokyo Stock Exchange]] through an [[initial public offering]] (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader [[Takeda Pharmaceutical Company]].<ref name=fujitoslodkowski2010/> The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.<ref name=fujitoslodkowski2010>{{Citation |last1=Fujita |first1=Junko |first2=Antoni |last2=Slodkowski |editor=Nathan Layne |date=December 16, 2010 |publisher=[[Forexyard]] |accessdate=January 15, 2012 |title=Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1 |type=[[Reuters]] news |at=forexyard.com |url=http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 |url-status=dead |archiveurl=https://web.archive.org/web/20120304221059/http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 |archivedate=March 4, 2012 }}</ref>
OPC's parent company Otsuka Holdings Co. Ltd. joined the [[Tokyo Stock Exchange]] through an [[initial public offering]] (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader [[Takeda Pharmaceutical Company]].<ref name=fujitoslodkowski2010/> The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.<ref name=fujitoslodkowski2010>{{Citation |last1=Fujita |first1=Junko |first2=Antoni |last2=Slodkowski |editor=Nathan Layne |date=December 16, 2010 |publisher=[[Forexyard]] |access-date=January 15, 2012 |title=Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1 |type=[[Reuters]] news |at=forexyard.com |url=http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 |url-status=dead |archive-url=https://web.archive.org/web/20120304221059/http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 |archive-date=March 4, 2012 }}</ref>


=== Otsuka Pharmaceutical Co. LTD Holdings ===
=== Otsuka Pharmaceutical Co. LTD Holdings ===


In 1955, the company started a [[football (soccer)|football]] club called "Otsuka Pharmaceutical SC." In 2005 the name changed to [[Tokushima Vortis]]. The club is based in Naruto.<ref>{{cite web |title=Tokushima Vortis |url=https://lostinfootballjapan.com/club-profiles/tokushima-vortis/ |accessdate=October 30, 2020}}</ref>
In 1955, the company started a [[football (soccer)|football]] club called "Otsuka Pharmaceutical SC." In 2005 the name changed to [[Tokushima Vortis]]. The club is based in Naruto.<ref>{{cite web |title=Tokushima Vortis |url=https://lostinfootballjapan.com/club-profiles/tokushima-vortis/ |access-date=October 30, 2020}}</ref>


In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of [[CG Roxane]].<ref>{{cite web |title=Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A. |url=https://www.otsuka.co.jp/en/company/newsreleases/2008/20080528_1.html |website=otsuka.co.jp |accessdate=October 30, 2020 |date=May 28, 2008}}</ref>
In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of [[CG Roxane]].<ref>{{cite web |title=Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A. |url=https://www.otsuka.co.jp/en/company/newsreleases/2008/20080528_1.html |website=otsuka.co.jp |access-date=October 30, 2020 |date=May 28, 2008}}</ref>


In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|author=|date=|website=GEN|accessdate=23 April 2018}}</ref>
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|website=GEN|access-date=23 April 2018}}</ref>


In July 2017, they bought [[Daiya]] <ref>{{Cite web|url=https://www.fooddive.com/news/plant-based-food-firm-daiya-bought-for-32597m-by-pharma-company-otsuka/448160/|title=Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka|website=Food Dive}}</ref>
In July 2017, they bought [[Daiya]] <ref>{{Cite web|url=https://www.fooddive.com/news/plant-based-food-firm-daiya-bought-for-32597m-by-pharma-company-otsuka/448160/|title=Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka|website=Food Dive}}</ref>
Line 76: Line 76:
* [[Pocari Sweat]]
* [[Pocari Sweat]]
* [[Oronamin C]]
* [[Oronamin C]]
* [[Aripiprazole|Aripiprazole / Abilify]]<ref name=Adis2019>{{cite web |title=Aripiprazole |url=http://adisinsight.springer.com/drugs/800001612 |publisher=AdisInsight |accessdate=4 June 2017}}</ref><ref>{{cite book |last1=Behere |first1=Prakash B. |last2=Das |first2=Anweshak |last3=Behere |first3=Aniruddh P. |title=Clinical Psychopharmacology: An Update |date=2018 |publisher=Springer |isbn=9789811320927 |page=66 |url=https://books.google.com/books?id=i9p1DwAAQBAJ&pg=PA66 }}</ref>
* [[Aripiprazole|Aripiprazole / Abilify]]<ref name=Adis2019>{{cite web |title=Aripiprazole |url=http://adisinsight.springer.com/drugs/800001612 |publisher=AdisInsight |access-date=4 June 2017}}</ref><ref>{{cite book |last1=Behere |first1=Prakash B. |last2=Das |first2=Anweshak |last3=Behere |first3=Aniruddh P. |title=Clinical Psychopharmacology: An Update |date=2018 |publisher=Springer |isbn=9789811320927 |page=66 |url=https://books.google.com/books?id=i9p1DwAAQBAJ&pg=PA66 }}</ref>


== Otsuka Holdings Co. Ltd. Holdings ==
== Otsuka Holdings Co. Ltd. Holdings ==
Line 82: Line 82:
In 1990, Otsuka Holdings Co. Ltd. acquired [[Crystal Geyser Water Company]]. <ref>https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf Otsuka.com Library], ''[[Otsuka Pharmaceutical]]''. Retrieved September 21, 2019.</ref>
In 1990, Otsuka Holdings Co. Ltd. acquired [[Crystal Geyser Water Company]]. <ref>https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf Otsuka.com Library], ''[[Otsuka Pharmaceutical]]''. Retrieved September 21, 2019.</ref>


In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".<ref name=biospace>{{Citation |date=January 13, 2012 |publisher=[[BioSpace]] |title=Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead |url=http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |accessdate=January 15, 2012 |archive-url=https://web.archive.org/web/20160303182456/http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |archive-date=March 3, 2016 |url-status=dead }}</ref> This decision necessitated a revision in the terms of an agreement with [[UCB (company)|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area.<ref>{{Citation |date=January 13, 2012 |accessdate=January 15, 2012|title=UCB and Otsuka to focus collaboration on CNS disorders |at=zenopa.com |publisher=[[Zenopa]]|url=http://www.zenopa.com/news/801263654/UCB_and_Otsuka_to_focus_collaboration_on_CNS_disorders }}</ref>
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".<ref name=biospace>{{Citation |date=January 13, 2012 |publisher=[[BioSpace]] |title=Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead |url=http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |access-date=January 15, 2012 |archive-url=https://web.archive.org/web/20160303182456/http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |archive-date=March 3, 2016 |url-status=dead }}</ref> This decision necessitated a revision in the terms of an agreement with [[UCB (company)|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area.<ref>{{Citation |date=January 13, 2012 |access-date=January 15, 2012|title=UCB and Otsuka to focus collaboration on CNS disorders |at=zenopa.com |publisher=[[Zenopa]]|url=http://www.zenopa.com/news/801263654/UCB_and_Otsuka_to_focus_collaboration_on_CNS_disorders }}</ref>


In September 2013, Otsuka Holdings it acquired [[Astex|Astex Pharmaceuticals]] for close to $900 million.<ref>{{cite news| url= https://www.reuters.com/article/2013/09/05/us-astex-offer-otsuka-idUSBRE98407Q20130905| title= Japan's Otsuka to buy cancer drug maker Astex Pharma| author= Tim Kelly| publisher=Reuters | date=5 September 2013}}</ref>
In September 2013, Otsuka Holdings it acquired [[Astex|Astex Pharmaceuticals]] for close to $900 million.<ref>{{cite news| url= https://www.reuters.com/article/2013/09/05/us-astex-offer-otsuka-idUSBRE98407Q20130905| title= Japan's Otsuka to buy cancer drug maker Astex Pharma| author= Tim Kelly| publisher=Reuters | date=5 September 2013}}</ref>


In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.<ref>{{cite web|url=https://dealbook.nytimes.com/2014/12/02/otsuka-of-japan-to-buy-avanir-pharmaceuticals-for-3-5-billion/?module=BlogPost-Title&version=Blog+Main&contentCollection=Mergers+&+Acquisitions&action=Click&pgtype=Blogs&region=Body|title=Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion|first=Jonathan|last=Soble|date=|website=nytimes.com|accessdate=23 April 2018}}</ref>
In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.<ref>{{cite web|url=https://dealbook.nytimes.com/2014/12/02/otsuka-of-japan-to-buy-avanir-pharmaceuticals-for-3-5-billion/?module=BlogPost-Title&version=Blog+Main&contentCollection=Mergers+&+Acquisitions&action=Click&pgtype=Blogs&region=Body|title=Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion|first=Jonathan|last=Soble|website=nytimes.com|access-date=23 April 2018}}</ref>


In July 2018, Otsuka Holdings acquired renal-focused ReCor Medical, Inc.<ref>{{Cite web|url=https://www.biospace.com/article/otsuka-medical-devices-otsuka-holdings-and-recor-medical-announce-signing-of-merger-agreement/|title=Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement|website=BioSpace}}</ref>
In July 2018, Otsuka Holdings acquired renal-focused ReCor Medical, Inc.<ref>{{Cite web|url=https://www.biospace.com/article/otsuka-medical-devices-otsuka-holdings-and-recor-medical-announce-signing-of-merger-agreement/|title=Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement|website=BioSpace}}</ref>

Revision as of 21:42, 16 December 2020

Otsuka Pharmaceutical Co., Ltd.
Native name
大塚製薬株式会社
Ōtsuka Seiyaku Kabushiki-gaisha
Company typePublic KK
TYO: 4578
TOPIX 100 Component
IndustryPharmaceutical
Founded1921 (Originally founded), 1964 (Current corporation)
FounderBusaburo Otsuka
Headquarters
Chiyoda, Tokyo
,
Japan
Number of locations
69
Area served
Worldwide
Key people
Tatsuo Higuchi (President)
Revenue¥ 531.2 billion (2017)
¥ 57.0 billion (2017)
OwnerNomura Trust and Banking investment trusts (11.43%)
and investment trusts managed by other banks
Number of employees
5,634 (2017)
ParentOtsuka Holdings Co. Ltd
Websiteotsuka.com
Products of Otsuka Pharmaceutical

Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.

History

OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company.[1] The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.[1]

Otsuka Pharmaceutical Co. LTD Holdings

In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.[2]

In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.[3]

In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.[4]

In July 2017, they bought Daiya [5]

In July 2018, Otsuka agreed to acquire Visterra for $430 million cash.[6]

Products

Otsuka Holdings Co. Ltd. Holdings

In 1990, Otsuka Holdings Co. Ltd. acquired Crystal Geyser Water Company. [9]

In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".[10] This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.[11]

In September 2013, Otsuka Holdings it acquired Astex Pharmaceuticals for close to $900 million.[12]

In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.[13]

In July 2018, Otsuka Holdings acquired renal-focused ReCor Medical, Inc.[14]

References

  1. ^ a b Fujita, Junko; Slodkowski, Antoni (December 16, 2010), Nathan Layne (ed.), Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1 (Reuters news), Forexyard, forexyard.com, archived from the original on March 4, 2012, retrieved January 15, 2012
  2. ^ "Tokushima Vortis". Retrieved October 30, 2020.
  3. ^ "Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A." otsuka.co.jp. May 28, 2008. Retrieved October 30, 2020.
  4. ^ "Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN". GEN. Retrieved 23 April 2018.
  5. ^ "Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka". Food Dive.
  6. ^ "Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms". July 11, 2018.
  7. ^ "Aripiprazole". AdisInsight. Retrieved 4 June 2017.
  8. ^ Behere, Prakash B.; Das, Anweshak; Behere, Aniruddh P. (2018). Clinical Psychopharmacology: An Update. Springer. p. 66. ISBN 9789811320927.
  9. ^ https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf Otsuka.com Library], Otsuka Pharmaceutical. Retrieved September 21, 2019.
  10. ^ Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead, BioSpace, January 13, 2012, archived from the original on March 3, 2016, retrieved January 15, 2012
  11. ^ UCB and Otsuka to focus collaboration on CNS disorders, Zenopa, January 13, 2012, zenopa.com, retrieved January 15, 2012
  12. ^ Tim Kelly (5 September 2013). "Japan's Otsuka to buy cancer drug maker Astex Pharma". Reuters.
  13. ^ Soble, Jonathan. "Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion". nytimes.com. Retrieved 23 April 2018.
  14. ^ "Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement". BioSpace.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Otsuka_Pharmaceutical&oldid=994661093"